Loading...
Please wait, while we are loading the content...
Similar Documents
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis
| Content Provider | Scilit |
|---|---|
| Author | Jung, Chul Won Shih, Lee-Yung Xiao, Zhijian Jie, Jin Hou, Hsin-An Du, Xin Wang, Ming-Chung Park, Seonyang Eom, Ki-Seong Oritani, Kenji Okamoto, Shinichiro Tauchi, Tetsuzo Kim, Jin Seok Zhou, Daobin Saito, Shigeki Li, Junmin Handa, Hiroshi Yong, Li Jian Ohishi, Kohshi Hou, Ming Depei, Wu Takenaka, Katsuto Liu, Ting Hu, Yu Amagasaki, Taro Ito, Kazuo Gopalakrishna, Prashanth Akashi, Koichi |
| Copyright Year | 2014 |
| Description | Myelofibrosis is characterized by progressive cytopenias, bone marrow fibrosis, splenomegaly and severe constitutional symptoms. In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy. No assessments of the efficacy and safety of ruxolitinib have been conducted in Asian patients. Here, we describe results from an open-label, single-arm, phase 2 trial evaluating ruxolitinib in Asian patients with myelofibrosis (n = 120). The primary endpoint was met, with 31.7% of patients achieving a ≥ 35% reduction from baseline spleen volume at week 24. As measured by the 7-day Myelofibrosis Symptom Assessment Form v2.0, 49% of patients achieved a ≥ 50% reduction from baseline in total symptom score. Adverse events were consistent with those seen in the COMFORT studies. Ruxolitinib was well tolerated in Asian patients with myelofibrosis and provided substantial reductions in splenomegaly and improvements in symptoms. |
| Related Links | https://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.969260?needAccess=true |
| Ending Page | 2074 |
| Page Count | 8 |
| Starting Page | 2067 |
| ISSN | 10428194 |
| e-ISSN | 10292403 |
| DOI | 10.3109/10428194.2014.969260 |
| Journal | Leukemia & Lymphoma |
| Issue Number | 7 |
| Volume Number | 56 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2014-11-20 |
| Access Restriction | Open |
| Subject Keyword | Journal: Leukemia & Lymphoma Hematology Research and Experimental Medicine Asian Patient Population Jak1/jak2 Inhibitor Myelofibrosis Phase 2 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology Cancer Research Oncology |
